Anthony Sung
Overview:
I am dedicated to the treatment of hematologic malignancies through cellular therapies such as hematopoietic stem cell transplantation (HCT). My research focuses on strategies to reduce complications of HCT and ranges from preclinical studies using murine models of HCT to Phase 1 and Phase 2 clinical trials. Areas of interest include the role of the microbiota (the trillions of bacteria living in and on our bodies), nutrition, and exercise in modulating HCT outcomes such as graft-versus-host disease (GVHD) and infections. In addition to advancing new pharmacological and cellular immunotherapies in support of these goals, we also are developing mobile health technologies (mHealth) to monitor patients at home, both as part of our innovative home transplant program as well as to improve follow up care of all our patients when they return home after transplant.
Positions:
Associate Professor of Medicine
Member of the Duke Cancer Institute
Senior Fellow in the Duke Center for the Study of Aging and Human Development
Education:
M.D. 2008
Residency, Osler Medical Housestaff Training Program
Fellowship, Hematology Oncology
Grants:
Patient-centered home-based hematopoietic stem cell transplantation
Keratinocyte targeted strategies for treatment of cutaneous GVHD
Mitigators of Radiation-Induced Endovascular Injury: Targeting Tie2 and Thrombocytopenia
Home Transplant to Preserve the Microbiota and Decrease GVHD
Development and Pilot Testing of a Hybrid In Person and mHealth Coping Skills Training Intervention for Symptom Management and Daily Steps in Stem Cell Transplant Patients
Publications:
Current status and future perspectives on the Internet of Things in oncology.
A SMART approach to optimizing delivery of an mHealth intervention among cancer survivors with posttraumatic stress symptoms.
Female Sex Is Associated with Improved Long-Term Survival Following Allogeneic Hematopoietic Stem Cell Transplantation.
Homecare Encounters: An Organizational Response to Innovative Care for Patients Undergoing Hematopoietic Stem Cell Transplantation During COVID-19.
Decreased Mortality in 1-Year Survivors of Umbilical Cord Blood Transplant vs. Matched Related or Matched Unrelated Donor Transplant in Patients with Hematologic Malignancies.
